Skip to main navigation Skip to search Skip to main content

Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients

  • Eric Lawitz
  • , Maribel Rodriguez-Torres
  • , Andrew J. Muir
  • , Tara L. Kieffer
  • , Lindsay McNair
  • , Ariya Khunvichai
  • , John G. McHutchison

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science